Abstracts Archive - Page 1507 of 2607 - ACR Meeting Abstracts

Abstract Number: 1796 • 2017 ACR/ARHP Annual Meeting
Benefits and Sustainability of a Learning Collaborative for Implementation of Treat to Target in Rheumatoid Arthritis: Results of Phase II of a Cluster Randomized Controlled Trial
Daniel H. Solomon¹, Liana Fraenkel², Zhi Yu³, Bing Lu⁴, Asaf Bitton⁵, Agnes Zak⁶, Cassandra Corrigan⁷, Jen Agosti⁸, Leslie R Harrold⁹, Josef S. Smolen¹⁰, Jeffrey N. Katz¹¹ and Elena Losina¹², ¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Rheumatology, Rheumatology, Yale University School of Medicine, New Haven, CT, New Haven, CT, ³Rheumatology Immunology & Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Medicine, Brigham and Women's Hospital, Boston, MA, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁸JRA Consulting, Andover, MA, ⁹University of Massachusetts Medical School, Worcester, MA, ¹⁰Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, ¹¹Rheumatology, Immunology, and Allergy, Brigham & Women's Hospital, Boston, MA, ¹²Orthopaedic and Arthritis Center for Outcomes Research, Department of Orthopedic Surgery, Brigham & Women's Hospital, Boston, MA
Background/Purpose: Treat to target (TTT) is a recommended strategy in the management of rheumatoid arthritis (RA), but its uptake in routine rheumatologic care in…
Abstract Number: 1797 • 2017 ACR/ARHP Annual Meeting
Insights from Treating to Target in Rheumatoid Arthritis at an Academic Medical Center
Malithi Jayasundara¹, Ryan Jessee², Jason Weiner³, Tayseer Haroun⁴, Stephanie Giattino⁵, Atul Kapila⁴, Jenelle Hall⁴, Lisa Carnago⁴ and Lisa Criscione-Schreiber⁶, ¹Rheumatology, Duke University, Durham, NC, ²Department of Medicine, Division of Rheumatology and Immunology, Duke University, Durham, NC, ³Department of Medicine, Division of Rheumatology and Immunology, Duke University Medical Center, Durham, NC, ⁴Duke University, Durham, NC, ⁵Rheumatology, Duke University Medical Center, Durham, NC, ⁶Internal Medicine, Duke University Medical Center, Durham, NC
Background/Purpose: Current RA guidelines recommend treating to a target of remission or low disease activity (RM/LDA) state. In a prior quality improvement (QI) project, our…
Abstract Number: 1798 • 2017 ACR/ARHP Annual Meeting
Effective Implementation and Evaluation of Quality Improvement Initiatives in a Safety Net Hospital Rheumatology Clinic
Alfredo Aguirre¹, Laura Trupin², Mary Margaretten³, Sarah Goglin⁴ and Jinoos Yazdany², ¹Internal Medicine, University of California, San Francisco, SAN FRANCISCO, CA, ²Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, ³Medicine, University of California San Francisco, San Francisco, CA, ⁴Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Vulnerable populations with autoimmune rheumatic diseases are at higher risk for disparities in care. To address these health inequalities we developed and evaluated 2…
Abstract Number: 1799 • 2017 ACR/ARHP Annual Meeting
Time to First Appointment Among Young Adults Transitioning from Pediatric to Adult Rheumatologic Care in a Safety Net Population
Nicole Bitencourt¹, Una E. Makris^1,2, Tracey Wright^3,4 and E. Blair Solow¹, ¹UT Southwestern Medical Center, Dallas, TX, ²Department of Medicine, VA North Texas Health Care System, Dallas, TX, ³Pediatrics/Rheumatology, UT Southwestern Medical Center, Dallas, TX, ⁴Texas Scottish Rite Hospital for Children, Dallas, TX
Background/Purpose: For young adults with a chronic rheumatic illness transitioning from pediatric to adult care, the transfer to new system can be daunting; these challenges…
Abstract Number: 1800 • 2017 ACR/ARHP Annual Meeting
Do Patient Reported Outcome Measurement Information System (PROMIS) Computer Adaptive Tests Correlate with Disease Activity in Juvenile Idiopathic Arthritis?
Rebecca Trachtman¹, Elizabeth T. Murray², Jackie Szymonifka³, Alexa Adams⁴, Nancy Pan⁴, Sarah Taber⁴, Thomas J. A. Lehman⁴, Karen Onel⁴ and Lisa A. Mandl⁵, ¹Pediatric Rheumatology, Hospital for Special Surgery Weill Cornell Medical College, NY, NY, ²Hospital for Special Surgery, New York, NY, ³Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Pediatric Rheumatology, Hospital for Special Surgery Weill Cornell Medical College, New York, NY, ⁵Rheumatology, Hospital for Special Surgery Weill Cornell Medical College, New York, NY
Background/Purpose: The importance of patient-reported outcomes is increasingly recognized both in clinical care and in research. PROMIS is an NIH-supported collection of patient-reported outcome measures,…
Abstract Number: 1801 • 2017 ACR/ARHP Annual Meeting
Quantifying Clinical and Economic Outcomes Associated with Chronic Corticosteroid Exposure in a US Population
J. Bradford Rice¹, Alan White¹, Andrea Lopez¹, Aneesha Wagh¹, Yimin Qin², Ghaith Mitri², Laura Bartels-Peculis², Gosia Ciepielewska² and Winnie Nelson³, ¹Analysis Group, Inc., Boston, MA, ²Mallinckrodt Pharmaceuticals, Hampton, NJ, ³Health Economics and Outcomes Research, Mallinckrodt Pharmaceuticals, Hampton, NJ
Background/Purpose: Corticosteroids (CS) are commonly used for rheumatologic conditions, and known to cause systemic adverse events (AEs), particularly when used at high doses for prolonged…
Abstract Number: 1802 • 2017 ACR/ARHP Annual Meeting
Detection of Flare over the Past 3 Months in Rheumatoid Arthritis: Cross-Cultural Equivalence of the Self-Report Flare-RA Questionnaire
Francis Guillemin¹, Marie-Line Erpelding², Annette de Thurah^3,4,5,6, Elena Myasoedova⁷, Emilce E Schneeberger⁸, Cynthia S. Crowson⁹, Thomas Maribo¹⁰, Gustavo Citera¹¹, Eric L. Matteson¹² and Bruno Fautrel¹³, ¹University of Lorraine, Nancy, France, Nancy, France, ²CIC 1433 Clinical Epidemiology, Inserm, Nancy, France, ³Department of Rheumatology, Aarhus University Hospital, Århus C, Denmark, ⁴Department of Rheumatology, Aarhus University Hospital, Aarhus, DK, Aarhus, Denmark, ⁵Department of Clinical Medicine, Aarhus University, Aarhus, Denmark, ⁶Department of Clinical Medicine, Aarhus University, Aarhus, DK, Aarhus N, Denmark, ⁷Rheumatology, Mayo Clinic, Rochester, MN, ⁸Section of Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina, ⁹Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ¹⁰DEFACTUM, Central Region Denmark, Aarhus, Denmark, ¹¹Section of Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina, ¹²Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ¹³UPMC University Paris 06, Pitié-Salpétrière Hospital, Paris, France
Background/Purpose: The Flare-RA questionnaire was developed and validated in French (1) for assessing the occurrence of a flare of rheumatoid arthritis (RA) during a 3-month…
Abstract Number: 1803 • 2017 ACR/ARHP Annual Meeting
A Cluster Analysis Approach to Patient-Physician Discordance in Rheumatoid Arthritis Activity Evaluations Optimally Differentiates and Predicts Clinical, Functional and Quality of Life Outcomes
George Karpouzas¹ and Sarah Ormseth², ¹Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ²Rheumatology, Harbor-UCLA Medical Center, Torrance, CA
Background/Purpose: Patients and physicians commonly differ in their evaluations of rheumatoid arthritis (RA) activity. However, clinically meaningful thresholds for such discordance or validation of their…
Abstract Number: 1804 • 2017 ACR/ARHP Annual Meeting
Patient-Reported Outcomes and Damage Predict Mortality in Lupus
Desiree R Azizoddin¹, Meenakshi Jolly², Patricia P. Katz³ and Edward H. Yelin⁴, ¹Department of Psychology, Loma Linda University, Loma Linda, CA, ²Rush, Chicago, IL, ³Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁴Medicine/Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Physician-assessed disease activity and damage predict mortality in systemic lupus erythematosus (SLE). Patient-reported outcomes (PROs) are known predictors of mortality in other chronic diseases,…
Abstract Number: 1805 • 2017 ACR/ARHP Annual Meeting
Construct Validity of RAPID3 for Measurement of Disease Activity in Psoriatic Arthritis
Jessica A. Walsh¹, Christine Willinger², M. Elaine Husni³, Soumya M. Reddy⁴, Jose U. Scher⁵ and Alexis Ogdie⁶, ¹Division of Rheumatology, University of Utah, Salt Lake City, UT, ²University of Pennsylvania, Philadelphia, PA, ³Cleveland Clinic, Cleveland, OH, ⁴Department of Medicine, Division of Rheumatology *contributed equally, New York University School of Medicine, New York, NY, ⁵New York University School of Medicine, New York, NY, ⁶Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: The Routine Assessment of Patient Index Data (RAPID3) was developed and validated for rheumatoid arthritis (RA). Little data exist on the use of RAPID3…
Abstract Number: 1806 • 2017 ACR/ARHP Annual Meeting
Performance of the Brief Index of Lupus Damage (BILD) in a Multi-Ethnic Population-Based Systemic Lupus Erythematosus (SLE) Cohort
Patricia P. Katz¹, Maria Dall'Era², Laura Trupin³, Stephanie Rush⁴, Charles G. Helmick⁵, Lindsey A. Criswell⁴ and Jinoos Yazdany³, ¹Medicine, University of California, San Francisco, San Francisco, CA, ²Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ³Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, ⁴University of California, San Francisco, San Francisco, CA, ⁵Centers for Disease Control and Prevention, Atlanta, GA
Background/Purpose: The BILD1,2 was developed and validated as a measure of SLE organ damage for use in epidemiologic studies in which administration of the SLICC…
Abstract Number: 1807 • 2017 ACR/ARHP Annual Meeting
Psychometric Evaluation of the Arthritis Research UK Musculoskeletal Health Questionnaire (MSK-HQ) in Inflammatory Arthritis
Sam Norton¹, Benjamin Ellis^2,3, Beatriz Santana Suárez⁴, Fowzia Ibrahim⁵, Andrew Price⁶, Ray Fitzpatrick⁶ and James Galloway⁷, ¹Academic Rheumatology, King´s College London, London, United Kingdom, ²Arthritis Research UK, Chesterfield, United Kingdom, ³Imperial College Healthcare NHS Trust, London, United Kingdom, ⁴Academic Rheumatology, King's College London, London, United Kingdom, ⁵Academic Rheumatology Dept, King's College London, London, United Kingdom, ⁶University of Oxford, Oxford, United Kingdom, ⁷King's College, and King´s College Hospital, London, United Kingdom
Background/Purpose: The Arthritis Research UK Musculoskeletal Health Questionnaire (MSK-HQ) is a recently developed patient reported outcome measure (PROM) for use across patients with different musculoskeletal…
Abstract Number: 1808 • 2017 ACR/ARHP Annual Meeting
Long-Term Immunogenicity of a Quadrivalent Human Papillomavirus Vaccine in Patients with Systemic Lupus Erythematosus
Chi Chiu Mok¹, Ling Yin Ho², Lai Shan Fong¹ and Chi Hung To³, ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Dept of Medicine, Tuen Mun Hospital, Hong Kong SAR, Hong Kong, ³Medicine, Pok Oi Hospital, Hong Kong, Hong Kong
Background/Purpose: To report the 5-year immunogenicity of a quadrivalent human papillomavirus (HPV) vaccine (GARDASIL) in patients with systemic lupus erythematosus (SLE). Methods: Female SLE patients…
Abstract Number: 1809 • 2017 ACR/ARHP Annual Meeting
Lack of Placental Transfer of Certolizumab Pegol during Pregnancy: Results from a Prospective, Postmarketing, Multicenter, Pharmacokinetic Study
Eliza Chakravarty¹, Frauke Förger², Bincy Abraham³, Ann Flynn⁴, Anna Moltó⁵, René-Marc Flipo⁶, Astrid van Tubergen⁷, Laura Shaughnessy⁸, Jeff Simpson⁸, Marie Teil⁹, Eric Helmer¹⁰, Maggie Wang⁸ and Xavier Mariette¹¹, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Department of Rheumatology and Clinical Immunology and Allergology, Inselspital, University of Bern, Bern, Switzerland, ³Houston Methodist Hospital, Houston, TX, ⁴University of Utah, Salt Lake City, UT, ⁵Hôpital Cochin, AP-HP, Paris, France, ⁶Centre Hospitalier Régional Universitaire de Lille, Lille, France, ⁷Maastricht University Medical Center, Maastricht, Netherlands, ⁸UCB Pharma, Raleigh, NC, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Brussels, Belgium, ¹¹INSERM U1184, Université Paris-Sud, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, France
Background/Purpose: There is a need for effective and safe treatment during pregnancy in women affected by chronic active inflammatory diseases such as rheumatoid arthritis. Adequate…
Abstract Number: 1810 • 2017 ACR/ARHP Annual Meeting
A Systematic Review of the Impact of Anti-Rheumatic Drugs upon Male Fertility and Paternal Exposure Peri-Conception
Julia D Flint¹, Maria Mouyis² and Ian Giles³, ¹Medicine, University College London, London, United Kingdom, ²Rheumatology Department, Northwick Park Hospital, London, United Kingdom, ³Centre for Rheumatology, University College London, Centre for Rheumatology, University College London, UK, London, United Kingdom
Background/Purpose: There is limited evidence relating to the impact of disease modifying anti-rheumatic drugs (DMARDs) upon male fertility and on pregnancies conceived by men with rheumatic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].